



#3

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Application of:  
Peter Dröge *et al.*

Serial No.: 10/082,772

Filed: February 25, 2002

For: SEQUENCE-SPECIFIC DNA  
RECOMBINATION IN EUKARYOTIC  
CELLS

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: DEBE:008US/SLH

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
March 28, 2002	
Date	Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10201861/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Steven L. Highlander", is written over a circular stamp that is partially obscured by the signature.

Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: March 28, 2002



TELEPHONE: 512/477-2201  
FACSIMILE: 512/536-4993

STEVEN L. HIGHLANDER  
PARTNER

INTERNET ADDRESS:  
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP


600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701

#318080350  
8/11/02  
HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

March 28, 2002

FILE: DEBE:008US

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
March 28, 2002	
Date	Steven L. Highlander

Commissioner for Patents  
Washington, DC 20231

RE: SN 10/082,772 "SEQUENCE-SPECIFIC DNA RECOMBINATION IN EUKARYOTIC CELLS" – Peter Dröge et al. (Client Reference: DRO-001 PCT/US BB/sch)


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (B1-B2, C1-C8).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10201861/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

  
Steven L. Highlander  
Reg. No. 37,642

SLH/cmb

Encl: as noted

Form PTO-1449 (modified)

Atty. Docket No.  
DEBE:008US/SLHSerial No.  
10/082,772

List of Patents and Publications for Applicant's

Applicant  
Peter Dröge *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
February 25, 2002Group:  
UnknownU.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 96/40722	12/19/96	PCT			
	B2	WO 97/47758	12/18/97	PCT			

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Christ and Dröge, "Alterations in the directionality of $\lambda$ site-specific recombination catalyzed by mutant integrases in vivo," <i>J. Mol. Biol.</i> , 288:825-836, 1999.
	C2	Database EMBL Sequences, Accession Code LAMCG, "Bacteriophage lambda genome," XP002164455, 1995.
	C3	Gu, <i>et al.</i> , "Deletion of a DNA polymerase $\beta$ gene segment in T cells using cell type-specific gene targeting," <i>Science</i> , 265:103-106, 1994.
	C4	Hoess, <i>et al.</i> , "Mechanism of strand cleavage and exchange in the Cre-lox site-specific recombination system," <i>J. Mol. Biol.</i> , 181:351-362, 1985.
	C5	Kilby, <i>et al.</i> , "Site-specific recombinases: tools for genome engineering," <i>Trends Genet.</i> , 9:413-421, 1993.
	C6	Landy, "Dynamic, structural, and regulatory aspects of $\lambda$ site-specific recombination," <i>Annu. Rev. Biochem.</i> , 58:913-949, 1989.
	C7	Lorbach <i>et al.</i> , "Site-specific recombination in human cells catalyzed by phage lambda integrase mutants," <i>J. Mol. Biol.</i> , 296:1175-1181, 2000.
	C8	Müller, "Ten years of gene targeting: targeted mouse mutants, from vector design to phenotype analysis," <i>Mech. Develop.</i> , 82:3-21, 1999.

25149122.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

